每年專案
個人檔案
學歷
- 2010 臺北醫學大學藥學系博士
- 2006 University of Sourhern CaliforniaPharmaceutical Sciences 碩士
- 2001 臺北醫學大學藥學系學士
經歷
- 2019.12- 臺北醫學大學生技醫療產業研發博士學程副研究員
- 2019.02- 臺北醫學大學生技醫藥商品化中心副研究員
- 2018.04-2019.01 臺北醫學大學生技醫藥商品化中心助理研究員
- 2016.11-2018.03 臺北醫學大學癌症轉譯研究中心助理研究員
- 2014.08-2016.10 臺北醫學大學轉譯醫學研究中心助理研究員
- 2013.01-2014.07 臺北醫學大學博士後研究員
- 2012.03-2012.10 食品藥物管理局審查員
- 2010.08-2012.02 臺北醫學大學博士後研究員
研究興趣
- 有機合成
指紋
查看啟用 Mei-Jung Lai 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
- 1 類似的個人檔案
過去五年中的合作和熱門研究領域
國家/地區層面的近期外部共同作業。按一下圓點深入探索詳細資料，或
專案
- 6 已完成
-
-
合成可雙重抑制組織蛋白去乙醯酶6與熱休克蛋白90，並同時調節PD-L1之雜環類抗癌化合物
Lai, M.-J. (PI)
8/1/20 → 7/1/21
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
組蛋白去乙醯酶在血管認知功能損傷中的作用-組蛋白去乙醯酶調節者在血管認知損傷動物可作為新的治療
Lai, M.-J. (PI)
1/1/19 → 12/1/19
研究計畫: A - 政府部門 › d - 教育部
-
-
-
Design and synthesis of polymer nanoparticles with pH-responsive pan-HDAC inhibitor (C5) derived from norbornene block copolymers to increase C5 solubility and improve its targeted delivery to prostate cancer sites
Mathew, J., Mishra, A., Le, T. N., Liou, J. P., Lai, M. J. & Rao Neralla, V., 2025, 於: Journal of Enzyme Inhibition and Medicinal Chemistry. 40, 1, 2530557.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取 -
Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies
Chen, I. C., Lin, H. Y., Liu, Z. Y., Cheng, W. J., Yeh, T. Y., Yang, W. B., Tran, H. Y., Lai, M. J., Wang, C. H., Kao, T. Y., Hung, C. Y., Huang, Y. L., Liou, K. C., Hsieh, C. M., Hsu, T. I. & Liou, J. P., 2025, 於: Journal of Medicinal Chemistry. 68, 3, p. 2779-2803 25 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取3 引文 斯高帕斯（Scopus） -
Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agents
Sethy, B., Yu, Z. Y., Narwanti, I., Upadhyay, R., Lai, M. J., Lee, S. B. & Liou, J. P., 12月 2024, 於: Bioorganic Chemistry. 153, 107771.研究成果: 雜誌貢獻 › 文章 › 同行評審
2 引文 斯高帕斯（Scopus） -
Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress
Sharma, R., Chiang, Y. H., Chen, H. C., Lin, H. Y., Yang, W. B., Nepali, K., Lai, M. J., Chen, K. Y., Liou, J. P. & Hsu, T. I., 4月 1 2024, 於: Cancer Letters. 586, 216666.研究成果: 雜誌貢獻 › 文章 › 同行評審
14 引文 斯高帕斯（Scopus） -
First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo
Sharma, S., Wang, S. A., Yang, W. B., Lin, H. Y., Lai, M. J., Chen, H. C., Kao, T. Y., Hsu, F. L., Nepali, K., Hsu, T. I. & Liou, J. P., 2月 22 2024, 於: Journal of Medicinal Chemistry. 67, 4, p. 2963-2985 23 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取6 引文 斯高帕斯（Scopus）
資料集
-
Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms
Lai, M.-J. (Creator), Lee, C.-H. (Creator), Chao, Y.-H. (Creator), Mehndiratta, S. (Creator), Chen, M.-C. (Creator), Liou, J.-P. (Creator) & Lee, H.-Y. (Creator), Taylor & Francis, 2020
DOI: 10.6084/m9.figshare.13207104.v1, https://tandf.figshare.com/articles/journal_contribution/Effect_of_3-subsitution_of_quinolinehydroxamic_acids_on_selectivity_of_histone_deacetylase_isoforms/13207104/1
資料集: Dataset
-
Additional file 4: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202896.v1, https://springernature.figshare.com/articles/Additional_file_4_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202896/1
資料集: Dataset
-
Additional file 5: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chang, L.-H. (Contributor), Liou, J.-P. (Creator), Lai, M.-J. (Contributor), Chang, C.-D. (Contributor), Tu, H.-J. (Contributor), Chao, M.-W. (Contributor), Pan, S.-L. (Contributor), Chen, Y.-Y. (Creator) & Teng, C.-M. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202902.v1, https://doi.org/10.6084%2Fm9.figshare.8202902.v1
資料集: Dataset
-
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.c.4522856.v1, https://springernature.figshare.com/collections/Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/4522856/1
資料集: Dataset
-
Additional file 1: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202881.v1, https://springernature.figshare.com/articles/Additional_file_1_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202881/1
資料集: Dataset